摘要
目的评价和比较三维适形放射治疗结合同步化疗与序贯化疗治疗Ⅲ期非小细胞肺癌(NSCLC)疗效。方法84例Ⅲ期患者随机分入同步治疗组和序贯治疗组。同步组第1周和第4周及三维适形放射治疗结束后行方案化疗(DDP:30mg/m2,d1～3,VP-16:100mg/m2,d1～5),共6周期。序贯组予2周期方案化疗后行三维适形放射治疗,放疗结束后继续完成4周期化疗。结果同步组和序贯组总有效率分别为83.3%和59.5%,有显著性差异(P<0.05);同步组患者1、2、3年生存率分别为67.8%、36.1%、20.8%,中位生存期为18.4个月;序贯组患者1、2、3年生存率分别为40.9%、25.8%、14.1%,中位生存期为13.3个月,两组比较有显著性差异(P<0.05)。两组不良反应除骨髓抑制外无显著性差异。结论三维适形放射治疗结合同步化疗治疗Ⅲ期NSCLC近期疗效较好,生存率提高,毒性也有所增加,但能为绝大多数患者耐受。
Objective To investigate the feasibility of threedimensional conformal radiotherapy （3D-CRT） plus concurrent cisplatin-based chemotherapy on the patients with stage Ⅲ non-small cell lung cancer （NSCLC）. Methods Eight-four cases with stage Ⅲ NSCLC were divided randomly into concurrent group and sequential group. Results The overall response rate （CR＋PR） in concurrent group and sequential group were 83.3% and 59.5% respectively, （P〈0.05）.The 1, 2, 3-year overall survival rate concurrent group and sequential group were 67.8%, 36.1%, 20.8% and 40.9%, 25.8%, 14.1% respectively. The median survival was 18.4 months, and 13.3months, respectively. And the difference of the toxicity （except leukocytopenia）was not statistically signifficant in two groups（P〉0.05）. Conclusion 3D-CRT combined with concurrent chemotherapy have better over response and shorter treatment couse than the sequential chemo-radioutheraphy, and increases the overall survival, so it is the best method for the treatment stage Ⅲ NSCLC.
出处
《当代医学》
2009年第34期66-68,共3页
Contemporary Medicine
关键词
非小细胞肺癌
三维适形放射治疗
放化疗同步治疗
序贯治疗
non-small cell lung cancer
three-dimensional conformal radiotherapy
concurrent chemotherapy
sequential chemotherapy
